1,721,399 research outputs found
Toward the future of the functional imaging of advanced prostate cancer.
No full textBS and CT are routinely used to assess the presence of metastases in advanced PCa patients. New imaging modalities such as PET and WB-MRI have the potential to replace previous imaging techniques allowing to earlier shift to more adequate therapies
En-bloc resection of non-muscle invasive bladder cancer: does it really make a difference?
No full textPurpose of review: Transurethral resection of bladder tumour (TURBT) followed by pathology investigation of the obtained specimens is the initial step in the management of urinary bladder cancer (UBC). By following the basic principles of oncological surgery, en-bloc resection of bladder tumour (ERBT) aims to overcome the limitations associated with conventional transurethral resection, and to improve the quality of pathological specimens for a better decision making. The current bulk of evidence provides controversial results regarding the superiority of one technique over the other. The aim of this article is to summarize the recent data and provide evidence on this unanswered question. Recent findings: Despite heterogeneous and controversial data, ERBT seems to have a better safety profile and deliver higher quality pathologic specimens. However, the recent evidence failed to support the hypothesized oncological potential benefits of ERBT in the initial surgical treatment of patients with UBC. Summary: ERBT has gained increasing interest globally in the past decade. It continues to represent a promising strategy with a variety of features intended to solve the inherent limitations of TURBT. However, the current quality of evidence does not allow solid conclusions to be drawn about its presumed superiority compared with the conventional technique
CARCINOMA A CELLULE TRANSIZIONALE PLASMOCITOIDE DELLE VESCICA: CASE REPORT
No full textCARCINOMA A CELLULE TRANSIZIONALE PLASMOCITOIDE DELLE VESCICA: CASE REPOR
DUPLICE ENUCLEORESEZIONE RENALE ROBOTICA CON ACCESSO RETROPERITONEALE IN PAZIENTE CON PREGRESSA CHIRURGIA ADDOMINALE, TROMBOCITOPENIA CRONICA E CIRROSI EPATICA
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma
No full textBackground
Several models are adopted in clinical practice to estimate prognosis of patients with metastatic renal cell carcinoma (mRCC); however, none of these models have evaluated patients treated by immune-checkpoint inhibitors. The aim of this study was to investigate if the site of initial metastasis could be a parameter able to stratified prognosis among patients with mRCC among different risk groups defined by the International Metastatic Renal Cell Database Consortium (IMDC) model. The site of initial metastasis was defined as the primary tissue or organ in which metastasis was diagnosed in the course of the medical history of the disease.
Patients and Methods
A total of 134 patients treated between January 2010 and December 2018 in our institution were retrospectively evaluated. The primary outcome was overall survival (OS) defined as the time from initiation of first-line therapy to death from any cause. Of note, 26 (19.4%) patients received immune-checkpoint inhibitors. Univariable analysis was performed through the log-rank test to estimate the effect of number of metastatic sites and site of initial metastasis on OS. Subsequently, a Cox regression proportional hazards model was employed in multivariable analysis.
Results
Of the 12 variables analyzed, 4 were statistically associated to worse OS in univariable analysis (number of metastases and liver, bone, or central nervous system metastases). Multivariate analysis confirmed that bone (hazard ratio [HR], 1.92; 95% confidence interval [CI], 1.17-3.13), liver (HR, 2.65; 95% CI, 1.59-4.42), and central nervous system (HR, 3.3; 95% CI, 1.62-6.74) initial metastases were independent parameters related to worse OS. The presence of 1 or more of the selected sites recognized specific populations of patients associated to worse prognosis in both good (P = .003) and intermediate (P = .047) risk groups.
Conclusion
The site of initial metastasis defines specific populations of patients associated with worse prognosis in the good and intermediate IMDC groups
MULTIPLA NEFRECTOMIA PARZIALE ROBOTICA "CLAMPLESS", CON L'AUSILIO DI ECOGRAFIA INTRAOPERATORIA (TILEPRO®) IN PAZIENTE MONORENE CHIRURGICO
No full textRICOSTRUZIONE DELLO SFINTERE STRIATO IN CORSO DI PROSTATECTOMIA RADICALE RETRO PUBICA: VALUTAZIONE DELLA RIPRESA PRECOCE DELLA CONTINENZA URINARIA
No full text- …
